A

Accellacare | DuPage Medical Group

Research site
(Unclaimed)
Location
430 Warrenville Road, Suite B, Lisle, Illinois, United States of America

Site insights

Top conditions

Top treatments

Cetrelimab
TAR-200
Sasanlimab
Cisplatin
Gemcitabine

Parent organization

This site is a part of Accellacare

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 4 total trials

A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer (CREST)

The purpose of this study is to learn about the safety and effects of the study medicine (sasanlimab) in people with non-muscle invasive bladder canc...

Active, not recruiting
Non-muscle Invasive Bladder Cancer
Drug: Bacillus Calmette-Guerin
Drug: PF-06801591

The purpose of this study is to evaluate the anti-tumor effects of TAR-200 in combination with intravenous (IV) cetrelimab and IV cetrelimab alone.

Enrolling
Urinary Bladder Neoplasms
Biological: Cetrelimab
Drug: TAR-200

The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV)...

Enrolling
Urinary Bladder Neoplasms
Drug: TAR-200
Radiation: Conventional radiation therapy

The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab...

Enrolling
Urinary Bladder Neoplasms
Biological: Cetrelimab
Drug: TAR-200

Trial sponsors

J
Pfizer logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems